Antiangiogenesis: New frontiers in therapeutic development

Angiogenesis

Volumn 8, Issue 4, 2006, Pages 285-287

  LaMontagne, Kenneth R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FINGOLIMOD; GEFITINIB; IMMUNOMODULATING AGENT; LY 2157299; PCK 3145; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SUPERPARAMAGNETIC IRON OXIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BREAST CANCER; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL EDUCATION; PRIORITY JOURNAL; PROSTATE CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33644603820     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-005-9025-6     Document Type: Conference Paper

References (11)

1. Marler JJ, Fishman SJ, Kilroy SM et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 2005; 116: 38-45.
2. Dowlati A, Robertson K, Radivoyevitch T et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 2005; 11: 7938-44.
3. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities. Cancer Res 2005; 65: 2507-10.
4. Peng SB, Yan L, Xia X et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 2005; 22: 2293-304.
5. LaMontagne K, Littlewood-Evans A, Schnell C et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res (In press).
6. Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004; 7: 289-300.
7. Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-2.
8. Carano RA, Ross AL, Ross J et al. Quantification of tumor tissue populations by multispectral analysis. Magn Reon Med 2004; 51: 542-51.
9. Drevs J, Konerding MA, Wolloscheck T et al. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004; 7: 347-54.
10. Shukeir N, Garde S, Wu JJ et al. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs 2005; 16: 1045-51.
11. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005; 26: 513-23.